<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01329926</url>
  </required_header>
  <id_info>
    <org_study_id>NGN-9001</org_study_id>
    <nct_id>NCT01329926</nct_id>
  </id_info>
  <brief_title>Molecular Analysis of Human Neural Stem Cells</brief_title>
  <official_title>Molecular Analysis of Adult Human-derived Neural Stem Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NeuroGeneration</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NeuroGeneration</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to develop and optimize methods to isolate, propagate and&#xD;
      differentiate adult human neural stem cells from patients with degenerative neurological&#xD;
      disorders like Parkinson's disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this project the investigators propose to analyze tissue samples from different nervous&#xD;
      system regions obtained during neurosurgical procedures in order investigate the presence of&#xD;
      neural stem cells in different cerebral areas. The investigators will also evaluate&#xD;
      techniques for neural stem cell cryopreservation, for possible future therapeutic uses.&#xD;
      Patients with degenerative neurological disorders like Parkinson's disease undergoing&#xD;
      neurosurgical procedures meeting our selection criteria will be candidate for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>June 30, 2011</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Neuronal differentiation into dopaminergic neurons</measure>
    <time_frame>6 months</time_frame>
    <description>Differentiation of at least 10% of dopaminergic neurons is targeted as the primary outcome measure</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Parkinson's Disease</condition>
  <condition>Parkinsonism</condition>
  <arm_group>
    <arm_group_label>Neural stem cells</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Harvesting of neural stem cells</intervention_name>
    <description>During neurosurgical procedures, tissue samples are obtained along trajectory of implanted electrodes or removal of stimulators previously implanted.</description>
    <arm_group_label>Neural stem cells</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Brain tissue obtained during neurosurgical procedures yields undifferentiated neural stem&#xD;
      cells that are subsequently expanded.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Parkinson's disease or parkinsonism&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Able to give informed consent prior to study&#xD;
&#xD;
          2. Male or Female with Diagnostic Criteria of Parkinson's disease or neurodegenerative&#xD;
             disorder undergoing a neurosurgical procedure&#xD;
&#xD;
          3. Age 35 to 85 years old&#xD;
&#xD;
          4. Parkinson's disease not due to trauma, infection, brain tumor, cerebrovascular disease&#xD;
&#xD;
          5. Hoehn and Yahr Stage III or IV&#xD;
&#xD;
          6. Parkinson's disease observed in the absence of:&#xD;
&#xD;
               -  Oculomotor palsy&#xD;
&#xD;
               -  Cerebellar sign&#xD;
&#xD;
               -  Orthostatic hypotension (drop greater than 20mmHg in mean pressure)&#xD;
&#xD;
               -  Pyramidal sign&#xD;
&#xD;
               -  Amyotrophy&#xD;
&#xD;
          7. Good general health or stable medical condition well controlled, without&#xD;
             contraindications to anesthesia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with severe dementia and brain atrophy on MRI&#xD;
&#xD;
          2. Patients with severe hypertension; renal, liver, cardiac or other major organ disease;&#xD;
             coagulopathy; cancer; other significant systemic illnesses; hepatitis, HIV&#xD;
&#xD;
          3. Patients older than 85 or younger than 35&#xD;
&#xD;
          4. Patients who withhold informed consent&#xD;
&#xD;
          5. Patients with a history of alcohol or drug abuse&#xD;
&#xD;
          6. Sexually active women of childbearing potential without adequate form of birth control&#xD;
&#xD;
          7. Evidence of abnormal coagulation or anticoagulant therapy&#xD;
&#xD;
          8. Pregnancy or lactation&#xD;
&#xD;
          9. History of seizure disorders or current use of antiepileptic medication&#xD;
&#xD;
         10. Severe cognitive impairment&#xD;
&#xD;
         11. Clinically significant laboratory abnormality&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michel F Levesque, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Los Angeles Neurosurgical Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Los Angeles Neurosurgical Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 31, 2011</study_first_submitted>
  <study_first_submitted_qc>April 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2011</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>NeuroGeneration</investigator_affiliation>
    <investigator_full_name>Michel F. Levesque, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Parkinson's disease</keyword>
  <keyword>Neural stem cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Parkinsonian Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

